82%Confidence
0Views
FDASource
2026-03-10Date
Summary
LEO Pharma recalls Adbry due to wool fiber contamination, a Class II sterility issue for a biologic injection. This specific particulate matter points to potential packaging or environmental control failures during manufacturing.
Actionable: Evaluate LEO Pharma's quality control response and monitor for any impact on Adbry's market share against competing atopic dermatitis treatments.
AI Confidence: 82%
Data Points
firmLEO PHARMA INC
classificationClass II
statusOngoing
distributionNationwide in the USA
productAdbry, (tralokinumab-ldrm) injection, 300 mg/2mL, Packaged as a) 1 x Single dose Autoinjector, SAMPLE NOT FOR SALE, NDC 50222-350-91; b) 2 x Single do
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now